OCMF 2021
Distinguished Keynote Speakers
Uri Ben-David, PhD
Genomic and functional approaches to modeling and targeting cancer aneuploidy
Tel Aviv University
Dennis Slamon, MD
Development and characterization of an anti-Claudin-6 (CLDN6) Antibody-Drug Conjugate for the treatment of CLDN6 positive cancer
University of California, Los Angeles
2021 Speakers
The Origins of Ovarian Precancer Species Ie-Ming Shih, M.D., Ph.D. John Hopkins Medicine Opportunistic Salpingectomy: Is it more than just a good idea? David Huntsman, M.D. University of British Columbia Salpingectomy for ovarian cancer risk reduction in high risk women Karen Lu, M.D. University of Texas MD Anderson Cancer Center Early detection of cancer using cell-free DNA fragmentomes Victor Velculescu, M.D., Ph.D. Johns Hopkins Medicine Utero-tubal lavage for diagnosis of ovarian cancer Keren Levanon, M.D., Ph.D. Tel Aviv University Chaim Sheba Medical Center Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with Nanoengineered Microfluidic Platforms Andrew Godwin, Ph.D. University of Kansas Medical Center Exploring the CINful side of high-grade serous ovarian cancer Kirk McManus, Ph.D. University of Manitoba Epigenetic control in tumor immunityand therapy Weiping Zou, M.D., Ph.D. University of Michigan Medical School Malignant and immune cell phenotypic states in high grade serous ovarian cancer Sohrab Shah, Ph.D. Memorial Sloan Kettering Cancer Center Interconnectivity of cell death pathways Ilana Chefetz, Ph.D. The Hormel Institute, University of Minnesota A novel humanized stroma PDX model for therapeutic studies Ron Buckanovich, M.D., Ph.D. University of Pittsburgh Targeting CCNE1 amplification in ovarian cancer…new approaches Fiona Simpkins, M.D. University of Pennsylvania School of Medicine Genomic and functional approaches to modeling and targeting cancer aneuploidy Uri Ben-David, PhD Tel Aviv University
Development and characterization of an anti-Claudin-6 (CLDN6) Antibody-Drug Conjugate for the treatment of CLDN6 positive cancer Featured Keynote: Dennis Slamon, M.D., Ph.D. University of California at Los Angeles Targeting Microtubule-Associated Protein Tau in Paclitaxel-sensitive and resistant Models in Ovarian Carcinoma Maria Barbolina, Ph.D. University of Illinois Cancer Center Chromosomal instability sensitizes to paclitaxel Beth Weaver, Ph.D. University of Wisconsin Determinants of p53-dependent tissue-specific gene expression and radio-resistance in vivo James Manfredi, Ph.D. Icahn School of Medicine at Mount Sinai Are ovarian cancers addicted to aneuploidy? Jason Sheltzer, Ph.D. Cold Spring Harbor Laboratory Mechanisms of chromosomal instability indicate therapeutic sensitivities in high grade serous ovarian carcinoma Sarah McClelland, Ph.D. Barts Cancer Institute The DoD OCRP, the Ovarian Cancer Academy and how to apply Karen Wylie, Ph.D. Department of Defense Ovarian Cancer Research Program What is the problem with our access to clinical trials? Rahel Ghebre, M.D., M.S. University of Minnesota Medical School Treatment of Ovarian Cancer: The World Beyond PARP inhibition Kathleen Moore, M.D. University of Oklahoma College of Medicine Targeting Replication Stress in Ovarian Cancer Panagiotis Konstantinopoulos, M.D., Ph.D. Harvard Cancer Center Novel agent combinations: Targeting adaptive and resistance response Stéphanie Lheureux, M.D., Ph.D. University of Toronto Moving beyond PARP inhibitors: Progress, Pitfalls and Promises Timothy Yap, Ph.D. University of Texas MD Anderson Cancer Center
Photos
